UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 15, 2005
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 000-32085 | 36-4392754 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
222 Merchandise Mart, Suite 2024
Chicago, IL 60654
Registrant’s telephone number, including area code (312) 506-1200.
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| ITEM 7.01. | Regulation FD Disclosure. |
Attached as Exhibit 99 hereto is an investor presentation dated August 2005, which is incorporated herein by reference.
This information is being furnished pursuant to Item 9 of this Report and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by Allscripts Healthcare Solutions, Inc. under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference. This Report will not be deemed an admission as to the materiality of any information in this Report that is being disclosed pursuant to Regulation FD.
Please refer to page 3 of Exhibit 99 for a discussion of certain forward-looking statements included therein and the risks and uncertainties related thereto.
| ITEM 9.01. | Financial Statements, Pro Forma Financial Information and Exhibits. |
| (c) | Exhibits: |
| 99 | Investor Presentation dated August 2005 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. | ||||||||
| Date: August 15, 2005 |
By: | /S/ WILLIAM J. DAVIS | ||||||
| William J. Davis Chief Financial Officer | ||||||||
3
EXHIBIT INDEX
The following exhibit is filed herewith:
| Exhibit No. |
||
| 99 | Investor Presentation dated August 2005. | |
Exhibit 99
ALLSCRIPTS TM
Inform. Connect. Transform.
1
Allscripts Overview
2
Safe Harbor
This presentation may contain forward-looking statements about Allscripts Healthcare Solutions that involve risks and uncertainties. These statements are developed by combining currently available information with Allscripts’ beliefs and assumptions. Forward-looking statements do not guarantee future performance. Because Allscripts cannot predict all of the risks and uncertainties that may affect it, or control the ones it does predict, Allscripts’ actual results may be materially different from the results expressed in its forward-looking statements. For a more complete discussion of the risks, uncertainties and assumptions that may affect Allscripts, see the Company’s 2004 Annual Report on Form 10-K, available at www.sec.gov.
3
What We Do & Who We Are . . .
We Provide Clinical Software, Connectivity & Information Solutions to Physicians
360 Employees
Public (Nasdaq: MDRX)
Financial Strength $130+ Million in Cash Reserves $100+ Million in 2004 Revenue
Diversified/Multiple Revenue Streams
The Leader in High Growth Markets
Culture
Fast Moving, Client-Focused and Innovative
4
Our Vision
To Become an Indispensable Part of the Way Physicians Practice Medicine
5
Our Solutions
Clinical Solutions Group
Electronic Health Record (EHR)
E-Prescribing
Document Imaging
Physicians Interactive Group e-Detailing
Patients Interactive iHealth
Medication Services Group
Pre-Packaged Medications
6
7
Clinical Solutions:
EHR Market Opportunity $5-6 Billion Market
The Market Has “Tipped”
> 25% Penetration of Mid to Large Size Groups
50% of Groups Purchasing in Next 18 Months*
Average deal size was approximately $600,000 in Q1’05
Pipeline continues to grow. We also expect average deal size to grow and include individual deals in $3 to $5 million range over the next 12 to 18 mo.
What Changed?
Tools & Technology are Better, Less Expensive Physicians’ Willingness to Adopt Technology Political, Payors, PBM, Patient Trends Results (Proven, Measurable ROI)
•source: PricewatershouseCoopers Study
Clinical Solutions:
Allscripts EHR – Competitive Advantages
Physician-Centric Approach
IDX Alliance = Preferred Access to 70% of Large Groups Modular Approach Drives Rapid Adoption and ROI Independent, Documented Return-On-Investment Blue-Chip Client Base Partners Play a Key Role in Our Solutions and Connections Organizing & Leading the Ambulatory Market
8
Clinical Solutions:
Allscripts EHR—Results
Sales Growth In Excess of 60%
Ranked #1 in KLAS, the “Consumer Reports’ of Healthcare, Ambulatory EHR Perception Report
Ranked #1 at TEPR Competition
Ranked #1 MS-HUG Awards
Central Utah Clinic Saves $1,000,000 in First Year
9
10
Clinical Solutions:
Allscripts EHR—Results
Over 1,500 Clinics Across the U.S.
11
Physicians Interactive:
Opportunity
The Opportunity
Pharma Industry Marketing Spend = $15 Billion/Year
Current Market for Online Product Education ~$250mm
The Pharma Challenge
Goal = Educate/Influence ~ 200,000 HVP’s Challenge = HVP’s Crunched For Time 43% of Pharma Detail Calls End at Receptionist 50% of Detail Calls Last < 2 Minutes
12
Physicians Interactive:
Results
Pioneer/Leading Provider of e-Detailing and Other Online Solutions
Blue Chip Client Base
39 Pharmaceutical, Biotech & Medical Device Companies
8 of Top 10 Pharmaceutical Companies
More Programs Delivered
400 Programs for 100 Brands
59 International Programs in 8 Countries
Significant Footprint with Physicians
60,000 Unique Physician Participants in U.S.
> 250,000 Educational Sessions Completed
13
Medication Services:
Results
Legacy Business
Continued Increases In Gross Margin Strength in Occupational Health Centers Strength in Employers On-Site Delivery
14
Financial Overview:
Revenue Growth Expected to Continue
(in millions) $100 $50 $0
Growth Segments
Medication Distribution Segment
2001 2002 2003 2004 2005 E
15
Financial Overview:
Translating into Positive EPS Growth $0.30 $0.22—$0.24
-$0.40
2002
2003
2004
2005 E
16
Financial Overview:
Backlog as of June 30,2005 (in millions) $76.3 Million $80 $70 $60 $50 $40 $30 $20 $10 $0
CSG Maint. / Support $12.1 $13.2 $10.5 $40.5
PI
CSG Subscriptions
CSG License/ Implmt. Fees
17
Financial Overview:
Financial Position as of June 30, 2005 (in millions)
Cash & Marketable Securities $134.9
Accounts Receivable, Net 23.3
Other Assets 44.1
Total Assets $202.3
Accounts Payable & Accrued Liabilities $17.5
Deferred Revenue 14.4
Convertible Debt 82.5
Other Liabilities 0.4
Total Liabilities 114.8
Stockholders’ Equity 87.5
Total Liabilities & Stockholders’ Equity $202.3
18
Summary
Physician-Centric
Competitive Advantage In Key Markets Strong Sales Momentum in Growing Markets Continued Increases In Gross Margin Leadership Position in All Businesses Strong Financial Position People
Bottom Line
Well Positioned for Growth and Sustained Profitability
19
ALLSCRIPTS TM
Inform . Connect . Transform .